Seattle Genetics Stock News

Cedar Brook Financial Partners LLC lessened its holdings in Seagen Inc. (NASDAQ:SGEN) by 18.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,435 shares of the biotechnology companys stock after selling 318 shares during the quarter. Cedar Brook Financial Partners []

The CHMP gives a positive opinion on, and recommends approval to Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.

The CHMP gives a positive opinion on, and recommends approval to Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.

Related Stocks: DFS , FANG , PGNY , RCL , BILL , SGEN , AVLR , TECH , ROKU , FOUR , PINS , LPLA , VEEV , PCTY , TTWO , ELS , SPOT , ZEN , FICO , FIVN , NVRO , EXAS ,

State of New Jersey Common Pension Fund D trimmed its holdings in Seagen Inc. (NASDAQ:SGEN) by 0.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 81,384 shares of the biotechnology companys stock after selling 76 shares during the period. State of New Jersey Common []

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) and Seagen Inc. (SGEN) said the CHMP of the European Medicines Agency has adopted a positive opinion, recommending approval

(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) and Seagen Inc. (SGEN) said the CHMP of the European Medicines Agency has adopted a positive opinion, recommending approval of the antibody-drug conjugate PADCEV or enfortumab vedotin, as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have

TOKYO & BOTHELL, Wash.--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas) and Seagen Inc. (Nasdaq:SGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of the antibody-drug conjugate (ADC) PADCEV (enfortumab vedotin) as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer

The Common Cancer-associated Antigens (CAAs) Vaccine research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and

DUBLIN--(BUSINESS WIRE)--The "Marine Pharmaceuticals Global Market Insights 2021, Analysis and Forecast to 2026, by Manufacturers, Regions, Technology, Application, Product Type" report has been added to ResearchAndMarkets.com''s offering. This report describes the global market size of Marine Pharmaceuticals from 2016 to 2020 and its CAGR from 2016 to 2020, and also forecasts its market size to the end of 2026 and its CAGR from 2021 to 2026. For the geography segment, regional supply, demand, m

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

Seagen Inc. (Nasdaq:SGEN) today announced promising efficacy and safety results from Part B of an open-label, phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in a novel combination with nivolumab, doxorubicin, and dacarbazine (AN+AD) as a frontline treatment for patients with advanced stage classical Hodgkin lymphoma (cHL). Data from this preliminary analysis were presented (Abstract

These stocks could be just what you need to put in your stocking.

These stocks could be just what you need to put in your stocking.

Sales are climbing at these biotech companies -- and more potential products are on the horizon.